Immunotherapy

2.3(top 20%)

impact factor

1.6K(top 10%)

papers

28.4K(top 10%)

citations

67(top 10%)

h-index

2.7(top 20%)

impact factor

2.2K

all documents

30.6K

doc citations

96(top 10%)

g-index

Top Articles

#	Title	Journal	Year	Citations
1	Immunotherapeutic implications of IL-6 blockade for cytokine storm	Immunotherapy	2016	521
2	Tumor-associated macrophages: implications in cancer immunotherapy	Immunotherapy	2017	259
3	Toll-like receptor agonists in cancer therapy	Immunotherapy	2009	258
4	Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls	Immunotherapy	2010	189
5	Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors	Immunotherapy	2020	188
6	PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data	Immunotherapy	2017	162
7	Gold nanoparticles-mediated photothermal therapy and immunotherapy	Immunotherapy	2018	162
8	Recent progress in GM-CSF-based cancer immunotherapy	Immunotherapy	2017	154
9	Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside	Immunotherapy	2016	147
10	Targeting B-cell maturation antigen in multiple myeloma	Immunotherapy	2015	146
11	Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma	Immunotherapy	2015	141
12	Antibody-targeted nanoparticles for cancer therapy	Immunotherapy	2011	140
13	Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3⁺ T cells in pancreatic lymph nodes	Immunotherapy	2009	139
14	Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges	Immunotherapy	2016	139
15	The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis	Immunotherapy	2016	136
16	Naive, effector and memory CD8 T-cell trafficking: parallels and distinctions	Immunotherapy	2011	135
17	Targeting tumor-infiltrating macrophages to combat cancer	Immunotherapy	2013	135
18	Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential	Immunotherapy	2015	135
19	Use of allogeneic NK cells for cancer immunotherapy	Immunotherapy	2011	134
20	Immune recognition and rejection of allogeneic skin grafts	Immunotherapy	2011	125
21	Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma	Immunotherapy	2016	124
22	Re-education of macrophages as a therapeutic strategy in cancer	Immunotherapy	2019	124
23	Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies	Immunotherapy	2012	121
24	MUC1 immunotherapy	Immunotherapy	2010	120
25	Current advances in T-cell-based cancer immunotherapy	Immunotherapy	2014	119
26	Directing dendritic cell immunotherapy towards successful cancer treatment	Immunotherapy	2010	113
27	CD73–adenosine: a next-generation target in immuno-oncology	Immunotherapy	2016	110
28	Anti-inflammatory therapy for diabetic retinopathy	Immunotherapy	2011	109
29	Cancer radioimmunotherapy	Immunotherapy	2011	108
30	mTOR signaling, Tregs and immune modulation	Immunotherapy	2014	108
31	Enhancing tumor T cell infiltration to enable cancer immunotherapy	Immunotherapy	2019	108
32	Etanercept for the treatment of rheumatoid arthritis	Immunotherapy	2018	107
33	Current immunotherapy in rheumatoid arthritis	Immunotherapy	2013	105
34	Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy	Immunotherapy	2017	104
35	Immunity and immune suppression in human ovarian cancer	Immunotherapy	2011	102
36	Safety analysis ofex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study	Immunotherapy	2009	97
37	Dual role of macrophage in tumor immunity	Immunotherapy	2018	97
38	The future of immune checkpoint cancer therapy after PD-1 and CTLA-4	Immunotherapy	2017	94
39	Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution	Immunotherapy	2018	93
40	Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan–MUC1	Immunotherapy	2013	92
41	PD-1/PD-L1 in disease	Immunotherapy	2018	90
42	NK cells: immune cross-talk and therapeutic implications	Immunotherapy	2011	88
43	Cancer-associated fibroblasts as targets for immunotherapy	Immunotherapy	2012	88
44	Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme	Immunotherapy	2014	88
45	Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy	Immunotherapy	2014	88
46	Combination strategies to enhance antitumor ADCC	Immunotherapy	2012	87
47	Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer	Immunotherapy	2018	86
48	Future perspectives of therapeutic monoclonal antibodies	Immunotherapy	2019	85
49	Hybridoma technologies for antibody production	Immunotherapy	2011	84
50	Myeloid suppressor cells and immune modulation in lung cancer	Immunotherapy	2012	84

Scientometrics

Overviews

Citing Bodies

Immunotherapy

Top Articles